At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Nov 9, 2026 at 07:30 ET
Bicara Therapeutics reported Q3 2026 net loss of $71.2M ($1.04 per share), wider than the $36.3M loss a year ago, as R&D and G&A costs rose sharply to support the pivotal FORTIFI-HN01 trial. The company achieved substantial enrollment in the trial and expects interim topline data in mid-2027. Cash of $442.3M is expected to fund operations into H1 2029.
- Net loss of $71.2M in Q3 2026 vs $36.3M in Q3 2025
- EPS of -$1.04 vs consensus -$0.86 (miss of 20.9%)
- Revenue $0 (pre-revenue clinical-stage company)
- Cash, cash equivalents and marketable securities $442.3M as of Sep 30, 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access